ATE131814T1 - Arylalkylpiperidine-4-yl)methyl>-2-alpha-3,4,5- tetrahydro-1-(2h)-acenaphthylene-1-onederivate, ein verfahren für ihre herstellung und ihre verwendung als medikamente - Google Patents

Arylalkylpiperidine-4-yl)methyl>-2-alpha-3,4,5- tetrahydro-1-(2h)-acenaphthylene-1-onederivate, ein verfahren für ihre herstellung und ihre verwendung als medikamente

Info

Publication number
ATE131814T1
ATE131814T1 AT92109467T AT92109467T ATE131814T1 AT E131814 T1 ATE131814 T1 AT E131814T1 AT 92109467 T AT92109467 T AT 92109467T AT 92109467 T AT92109467 T AT 92109467T AT E131814 T1 ATE131814 T1 AT E131814T1
Authority
AT
Austria
Prior art keywords
loweralkoxy
hydrogen
arylalkylpiperidine
acenaphthylene
medications
Prior art date
Application number
AT92109467T
Other languages
English (en)
Inventor
Raymond W Kosley Jr
Bettina Spahl
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Application granted granted Critical
Publication of ATE131814T1 publication Critical patent/ATE131814T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Pyridine Compounds (AREA)
AT92109467T 1991-06-07 1992-06-04 Arylalkylpiperidine-4-yl)methyl>-2-alpha-3,4,5- tetrahydro-1-(2h)-acenaphthylene-1-onederivate, ein verfahren für ihre herstellung und ihre verwendung als medikamente ATE131814T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/713,249 US5106856A (en) 1991-06-07 1991-06-07 [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds

Publications (1)

Publication Number Publication Date
ATE131814T1 true ATE131814T1 (de) 1996-01-15

Family

ID=24865395

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92109467T ATE131814T1 (de) 1991-06-07 1992-06-04 Arylalkylpiperidine-4-yl)methyl>-2-alpha-3,4,5- tetrahydro-1-(2h)-acenaphthylene-1-onederivate, ein verfahren für ihre herstellung und ihre verwendung als medikamente

Country Status (23)

Country Link
US (1) US5106856A (de)
EP (1) EP0517221B1 (de)
JP (1) JP2961013B2 (de)
KR (1) KR100234445B1 (de)
AT (1) ATE131814T1 (de)
AU (1) AU646784B2 (de)
CA (1) CA2070714A1 (de)
CZ (1) CZ284591B6 (de)
DE (1) DE69206889T2 (de)
DK (1) DK0517221T3 (de)
ES (1) ES2081517T3 (de)
FI (1) FI101297B1 (de)
GR (1) GR3018558T3 (de)
HU (1) HU217967B (de)
IE (1) IE72199B1 (de)
IL (1) IL102118A (de)
MX (1) MX9202736A (de)
NO (1) NO178889C (de)
NZ (1) NZ243013A (de)
PL (1) PL169423B1 (de)
RU (1) RU2043989C1 (de)
TW (1) TW206214B (de)
ZA (1) ZA924109B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW248556B (de) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
EP1891954A3 (de) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Wirkstoffe zur Verbesserung der Exkretionskraft der Harnblase
BR112012019923A2 (pt) 2010-02-09 2016-08-09 Univ Johns Hopkins métodos e composições para melhorar a função cognitiva
EP2640391B1 (de) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazinderivate, zusammensetzungen und verfahren zur behandlung von kognitiven störungen
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968220B1 (de) 2013-03-15 2021-05-05 Agenebio, Inc. Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2015095783A1 (en) 2013-12-20 2015-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2589934A (en) * 1950-08-24 1952-03-18 Abbott Lab 2-aminomethyl-tetrahydroacenapthones-1 and their preparation
US3391178A (en) * 1964-12-30 1968-07-02 Ernest E. Campaigne Dialkylaminoalkyl 1-oxo-2alpha, 3, 4, 5-tetrahydroacenaphthen-2alpha-carboxylates
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
PL294803A1 (en) 1993-07-26
RU2043989C1 (ru) 1995-09-20
AU1801592A (en) 1992-12-10
JPH06116237A (ja) 1994-04-26
IE72199B1 (en) 1997-04-09
ES2081517T3 (es) 1996-03-16
DE69206889D1 (de) 1996-02-01
NO922223D0 (no) 1992-06-05
FI101297B (fi) 1998-05-29
NO922223L (no) 1992-12-08
FI922592A (fi) 1992-12-08
MX9202736A (es) 1993-01-01
NO178889B (no) 1996-03-18
EP0517221B1 (de) 1995-12-20
FI922592A0 (fi) 1992-06-04
NZ243013A (en) 1995-04-27
DE69206889T2 (de) 1996-05-30
HU217967B (hu) 2000-05-28
HUT65605A (en) 1994-07-28
HU9201887D0 (en) 1992-08-28
IE921840A1 (en) 1992-12-16
US5106856A (en) 1992-04-21
CA2070714A1 (en) 1992-12-08
FI101297B1 (fi) 1998-05-29
IL102118A (en) 1996-05-14
NO178889C (no) 1996-06-26
TW206214B (de) 1993-05-21
KR930000483A (ko) 1993-01-15
CS171392A3 (en) 1992-12-16
ZA924109B (en) 1993-02-24
CZ284591B6 (cs) 1999-01-13
AU646784B2 (en) 1994-03-03
EP0517221A1 (de) 1992-12-09
JP2961013B2 (ja) 1999-10-12
KR100234445B1 (ko) 1999-12-15
GR3018558T3 (en) 1996-03-31
IL102118A0 (en) 1993-01-14
DK0517221T3 (da) 1996-04-22
PL169423B1 (pl) 1996-07-31

Similar Documents

Publication Publication Date Title
ATE131814T1 (de) Arylalkylpiperidine-4-yl)methyl>-2-alpha-3,4,5- tetrahydro-1-(2h)-acenaphthylene-1-onederivate, ein verfahren für ihre herstellung und ihre verwendung als medikamente
ATE338754T1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
DE69025941D1 (de) Dem Physostigmin verwandte 4- und 6-Carbamate, ein Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE124695T1 (de) Kondensierte heterocyclische verbindungen, ihre herstellung und verwendung.
DE3772905D1 (de) Alpha-alkyl-4-amino-3-chinolin-methanole und 1-(4-aralkylamino-3-chinolyl)alkanone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE136297T1 (de) Substituierte 4-amino-3-pyridinolen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE140006T1 (de) 1-(pyrido(3,4-b>-1,4-oxazinyl-4-yl)-1h-indole, zwischenprodukte und ein verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69222444T2 (de) Substituierte 1,2,3,4-Tetrahydrocyclopent[b]indole, 1,2,3,3a,4,8a-Hexahydrocyclopent[b]indole und verwandte Verbindungen, Zwischenprodukte und ein Verfahren zur Herstellung derselben und ihre Verwendung als Medikamente
DE69223205T2 (de) Substituierte Pyridinylamino-1H-Indole, 1H-Indazole, 2H-Indazole, Benzo(b)thiophen und 1,2-Benzisothiazole, Verfahren zu ihren Herstellung und ihre Verwendung als Arzneimittel
DE3780015D1 (de) Kondensierte heterocyclische tetrahydroaminochinolinole und verwandte verbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE79118T1 (de) N-pyridinyl-9h-carbazol-9-amine, verfahren zu ihrer herstellung und ihre verwendung als medikamente.
ATE111899T1 (de) 1,2,3,4-tetrahydro-1,9-acridindiamine, ein verfahren zu ihrer herstellung und ihre verwendung als medikamente.
ATE178327T1 (de) 3-(1,thiazolidinylbutyl-4-piperazinyl>-1h- indazole, verfahren zu ihrer herstellung und ihre verwendung als medikamente
DE69915471D1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
ATE115133T1 (de) (1,2,3,4-tetrahydro-9-acridinimino)cyclohexan- carbonsäure und verwandte verbindungen, ein verfahren zu ihrer herstellung und ihre verwendung als medikamente.
ATE122047T1 (de) 4,5,5a,6-tetrahydro-3h-isoxyzolo(5,4,3- k1)acridinderivate, ein verfahren zu ihrer herstellung und ihre verwendung als medikamente.
ATE52510T1 (de) Benzo(c>-1,5-naphthyridine, ein verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als arzneimittel.
MX25922A (es) Pirido (3,4-b) pirrolo (1,2-e)(1,4,5)oxadiazepinasy compuestos analogos relacionados un procedimiento para su preparacion y su uso como medicamentos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee